IGC Pharma, Inc.IGC
Price (close)
$0.28
Market cap
$28.8M
P/E
—
Revenue (TTM)
$1.1M
Net income
-$7.9M
Dividend yield
—
1-year total return
-27.9%
Net margin
-702.1%
Revenue growth
-15.4%
Debt / equity
0.02x
What IGC Pharma, Inc. does.
a clinical-stage biotechnology company focused on the development of novel therapeutic candidates for neuropsychiatric and neurodegenerative
disorders, with a primary emphasis on Alzheimer’s disease. Our core strategy is to address high-burden symptoms and underlying disease
mechanisms through differentiated pharmaceutical formulations, supported by targeted clinical development and data-driven research approaches.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $898,000 | $397,000 | $911,000 | $1.3M | $1.3M | — |
| Net income | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M | — |
| Free cash flow | -$12.3M | -$7.7M | -$7.4M | -$5.3M | -$4.9M | — |
More on IGC.
- IGC Pharma, Inc. summary
- IGC Pharma, Inc. financial statements
- IGC Pharma, Inc. key metrics
- IGC Pharma, Inc. health scores and style box
- IGC Pharma, Inc. earnings
- IGC Pharma, Inc. dividends
- IGC Pharma, Inc. valuation
- IGC Pharma, Inc. ownership and insiders
- IGC Pharma, Inc. peers
Figures from IGC Pharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.